Memantine
- Generic Name
- Memantine
- Brand Names
- Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric, Nemdatine, Memantine Mylan, Memantine ratiopharm, Memantine Merz, Marixino (previously Maruxa), Memantine Accord, Memantine LEK
- Drug Type
- Small Molecule
- Chemical Formula
- C12H21N
- CAS Number
- 19982-08-2
- Unique Ingredient Identifier
- W8O17SJF3T
- Background
Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . ...
- Indication
Memantine is used to manage moderate to severe Alzheimer's dementia .
...
- Associated Conditions
- Alzheimer's Disease (AD), Moderate to Severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia
- Associated Therapies
- -
Dextromethorphan, Memantine Monotherapy, or Combined Use of Dextromethorphan and Memantine in Amphetamine Addiction
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04687566
- Locations
- 🇨🇳
Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
- Conditions
- Metastatic MelanomaPrognostic Stage IV Breast Cancer AJCC v8Metastatic Digestive System CarcinomaStage IV Renal Cell Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Malignant Neoplasm in the BrainStage IVB Lung Cancer AJCC v8Metastatic Lung Non-Small Cell Carcinoma
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 350
- Registration Number
- NCT04588246
- Locations
- 🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸City of Hope Corona, Corona, California, United States
Effect of Memantine on Cognitive Impairment in Patients With Epilepsy
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 100
- Registration Number
- NCT04417543
- Locations
- 🇪🇬
Salma Mohmed Fahmy, Assiut, Egypt
Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT04217694
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Monitoring Anti-Dementia Drugs by Serum Levels
- First Posted Date
- 2019-10-07
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Zealand University Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT04117178
- Locations
- 🇩🇰
Regionalt Videnscenter for Demens, Roskilde, Region Sjælland, Denmark
Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT04033419
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
A Study in Healthy Men and Women to Test Which Effects Memantine and BI 425809 Have on Each Other
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT03988803
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 42
- Registration Number
- NCT03860597
- Locations
- 🇺🇸
Clinical Teaching Facility (CTF-B102) at UCSD Medical Center, San Diego, California, United States
Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine
- First Posted Date
- 2019-02-28
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Wayne State University
- Target Recruit Count
- 50
- Registration Number
- NCT03858270
- Locations
- 🇺🇸
Wayne State University, Detroit, Michigan, United States
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 32
- Registration Number
- NCT03703856
- Locations
- 🇺🇸
Clinical Teaching Facility (CTF-B102) at UCSD Medical Center, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.